<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109611</article-id><article-id pub-id-type="doi">10.26442/00403660.2022.06.201558</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of hemostasis disorders using the thrombodynamic test in patients with chronic glomerulonephritis with nephrotic syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка нарушений гемостаза с использованием теста тромбодинамики у больных хроническим гломерулонефритом с нефротическим синдромом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6838-0754</contrib-id><name-alternatives><name xml:lang="en"><surname>Berns</surname><given-names>Angelina S.</given-names></name><name xml:lang="ru"><surname>Бернс</surname><given-names>Ангелина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8057-7616</contrib-id><name-alternatives><name xml:lang="en"><surname>Sovetnikov</surname><given-names>Egor N.</given-names></name><name xml:lang="ru"><surname>Советников</surname><given-names>Егор Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студент</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2128-8560</contrib-id><name-alternatives><name xml:lang="en"><surname>Chebotareva</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Чеботарева</surname><given-names>Наталья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1002-1895</contrib-id><name-alternatives><name xml:lang="en"><surname>Berns</surname><given-names>Svetlana A.</given-names></name><name xml:lang="ru"><surname>Бернс</surname><given-names>Светлана Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. терапии и общей практики Института профессионального образования и аккредитации</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0305-8251</contrib-id><name-alternatives><name xml:lang="en"><surname>Solonkina</surname><given-names>Alena D.</given-names></name><name xml:lang="ru"><surname>Солонкина</surname><given-names>Алена Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студент</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6138-4333</contrib-id><name-alternatives><name xml:lang="en"><surname>Guliaev</surname><given-names>Sergei V.</given-names></name><name xml:lang="ru"><surname>Гуляев</surname><given-names>Сергей Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2141-6411</contrib-id><name-alternatives><name xml:lang="en"><surname>Kraeva</surname><given-names>Valentina V.</given-names></name><name xml:lang="ru"><surname>Краева</surname><given-names>Валентина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7232-4640</contrib-id><name-alternatives><name xml:lang="en"><surname>Moiseev</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Моисеев</surname><given-names>Сергей Валентинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского, дир. Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3</p></bio><email>svberns@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Medical Research Center for Therapy and Preventive Medicine</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-08-04" publication-format="electronic"><day>04</day><month>08</month><year>2022</year></pub-date><volume>94</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>738</fpage><lpage>742</lpage><history><date date-type="received" iso-8601-date="2022-08-04"><day>04</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-04"><day>04</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/109611">https://ter-arkhiv.ru/0040-3660/article/view/109611</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Nephrotic syndrome (NS) is accompanied by a risk of thrombotic complications due to hypercoagulability. Routine laboratory tests are not sensitive enough to detect these disorders, and therefore the use of integral coagulation tests, including a new thrombodynamic test (TT) in patients with NS, is of high relevance.</p> <p><bold>Aim. </bold>Using a TT to determine hemostasis disorders in patients with chronic glomerulonephritis (CGN) with NS.</p> <p><bold>Materials and methods. </bold>The study included 49 patients with CGN, mean age 37 years, of which 25 (51%) women and 24 (49%) men. Of all the examined patients, 20 (40.8%) of people had NS, 29 (59.2%) had no NS. The process of clot formation was assessed by TT.</p> <p><bold>Results. </bold>According to TT, 30% (6/20) of patients with NS and 13.7% (4/29) of patients without NS have hypercoagulation with changes in parameters that go beyond the reference values. In patients with NS, an increase in clot density (D), clot formation rate (V) and clot size (CS) was found, especially when albumin decreased below 25 g/l. Negative correlations were found between the levels of albumin, creatinine and clot density (D), which reflects the level of hyperfibrinogenemia, the rate of clot formation (V) and the integral index of coagulation (CS). The results indicate mainly the activation of the plasma hemostasis due to the internal coagulation pathway. However, the correlation of Tlag (delay time for the onset of clot formation after contact of blood plasma with the insert-activator) with serum cholesterol levels may also indicate activation of the extrinsic coagulation pathway.</p> <p><bold>Conclusion. </bold>In CGN patients with NS, activation of the plasma hemostasis is noted, as evidenced by an increase in the rate of formation (V) and size of the clot (CS) after 30 minutes, as well as the density of the formed clot (D).</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Нефротический синдром (НС) сопровождается риском развития тромботических осложнений вследствие гиперкоагуляции. Рутинные лабораторные тесты недостаточно чувствительны для обнаружения этих нарушений, в связи с чем актуально применение интегральных тестов коагуляции, в том числе теста тромбодинамики (ТТД) у больных с НС.</p> <p><bold>Цель. </bold>При помощи ТТД определить нарушения гемостаза у больных хроническим гломерулонефритом (ХГН) с НС.</p> <p><bold>Материалы и методы. </bold>В исследование включены 49 больных ХГН, средний возраст 37 лет, из них 25 (51%) женщин и 24 (49%) мужчины. Из всех обследованных пациентов 20 (40,8%) человек имели НС, у 29 (59,2%) НС отсутствовал. Процесс формирования сгустка оценивали c помощью ТТД.</p> <p><bold>Результаты. </bold>По результатам ТТД у 30% (6/20) больных с НС и у 13,7% (4/29) пациентов без НС отмечена гиперкоагуляция с изменениями показателей, выходящими за референсные значения. У больных с НС обнаружено увеличение плотности (D), скорости образования (V) и размера (CS) сгустка, в особенности при снижении содержания альбумина &lt;25 г/л. Установлены обратные корреляции между концентрацией альбумина, креатинина и D, отражающие уровень гиперфибриногенемии, а также между V и интегральным показателем активации свертывания CS. Полученные результаты указывают преимущественно на активацию плазменного звена гемостаза по внутреннему пути свертывания. Однако корреляция показателя Tlag (время задержки начала образования сгустка после контакта плазмы крови со вставкой-активатором) с уровнем холестерина сыворотки может свидетельствовать и об активации внешнего пути свертывания.</p> <p><bold>Заключение. </bold>У больных ХГН с НС отмечается активация плазменного звена гемостаза, о чем свидетельствует увеличение показателей V и CS через 30 мин, а также плотности образованного сгустка D.</p></trans-abstract><kwd-group xml:lang="en"><kwd>nephrotic syndrome</kwd><kwd>blood coagulation disorders</kwd><kwd>thrombodynamics</kwd><kwd>hypoalbuminemia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>нефротический синдром</kwd><kwd>тест тромбодинамики</kwd><kwd>нарушения свертывания крови</kwd><kwd>гипоальбуминемия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron. 1993;63(3):249-54. DOI:10.1159/000187205</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202-11. DOI:10.1056/NEJM199804233381707</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost. 1997;23(3):271-80. DOI:10.1055/s-2007-996100</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Llach F, Kofﬂer A, Finck E, Massry SG. On the incidence of renal vein thrombosis in the nephrotic syndrome. Arch Intern Med. 1977;137:333-6.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res. 2006;118(3):397-407. DOI:10.1016/j.thromres.2005.03.030</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mahmoodi BK, ten Kate MK, Waanders F, et al. High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome: Results From a Large Retrospective Cohort Study. Circulation. 2008;117(2):224-30. DOI:10.1161/Circulationaha.107.716951</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zhang LJ, Zang Z, Li SJ, et al. Pulmonary Embolism and Renal Vein Thrombosis in Patients With Nephrotic Syndrome: Prospective Evaluation of Prevalence and Risk Factors With CT. Radiology. 2014;273(3):897-906. DOI:10.1148/radiol.14140121</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fahal IH, McClelland P, Hay CR, Bell JM. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J. 1994;70(830):905-9. DOI:10.1136/pgmj.70.830.905</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397-407. DOI:10.1016/j.thromres.2005.03.030</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Curry ANG, Pierce JMT. Conventional and near-patient tests of coagulation. Continuing Education in Anaesthesia. Anaesth Crit Care Pain Med. 2007;7(2):45-50. DOI:10.1093/BJACEACCP/MKM002</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yalсinkaya F, Tomer N, Gorgani AN, et al. Haemostatic parameters in childhood nephrotic syndrome. Int Urol Nephrol.1995;27(5):643-7. DOI:10.1007/BF02564753</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Panteleev MA, Hemker HC. Global/integral assays in hemostasis diagnostics: Promises, successes, problems and prospects. Thromb J. 2015;13(1):1-4. DOI:10.1186/s12959-014-0032-y</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sinauridze EI, Vuimo TA, Tarandovskiy ID, et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282-91. DOI:10.1016/j.talanta.2017.12.055</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fadeeva OA, Panteleev MA, Karamzin SS, et al. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochemistry (Mosc). 2010;75:734-43. DOI:10.1134/s0006297910060088</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Koltsova EM, Balandina AN, Grischuk KI, et al. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery. J Perinat Med. 2018;46:251-60. DOI:10.1515/jpm-2016-0333</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Balandina AN, Serebriyskiy II, Poletaev AV, et al. Thrombodynamics – a new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PLoS One. 2018;13(6):e0199900. DOI:10.1371/journal.pone.0199900</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Паршина С.С. Глобальный тест тромбодинамики в диагностике и лечении больных сердечно-сосудистой патологией. Бюллетень медицинских интернет-конференций. 2016;6(8):1437-8 [Parshina SS. Global thrombodynamics test in the diagnosis and treatment of patients with cardiovascular pathology. Bulletin of Medical Internet Conferences. 2016;6(8):1437-8 (in Russian)].</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gyamlani G, Miklos Z, Molnar MZ, et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32(1):157-64. DOI:10.1093/ndt/gfw227</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol. 2012;7(10):1584-90.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Singh J, Khadka S, Solanki D, et al. Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States. SAGE Open Med. 2021;3(9). DOI:10.1177/20503121211022996</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Owens AP 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122(2):558-68. DOI:10.1172/JCI58969</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Huang MJ, Wei RB, Wang ZC, et al. Mechanisms of hypercoagulability in nephrotic syndrome associated with membranous nephropathy as assessed by thromboelastography. Thromb Res. 2015;136(3):663-8.</mixed-citation></ref></ref-list></back></article>
